Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$39.72M, compared with -$17.35M a year earlier. Trailing-twelve-month net income was -$166.12M.
Context
- Net income amounted to 565.5% of revenue in FY2025, up 534.3 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$166.79M (-16.0%) for the fiscal year ending Dec 2026, a step up from the -319.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$39.72M-1.4% QoQ
- Last fiscal yearDec 2025
- -$143.75M-319.0% YoY
- LTMMar 2026
- -$166.12M-770.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -128.9% | -3.2% | +125.8 pp |
| 1 year | -319.0% | -16.0% | +303.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (143.75M) USD
- Year-over-year change
- -319.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (143.75M) | -319.0% |
| FY2024 | 2024-12-31 | 65.63M | +1081.7% |
| FY2023 | 2023-12-31 | (6.69M) | +92.9% |
| FY2022 | 2022-12-31 | (94.62M) | -84.9% |
| FY2021 | 2021-12-31 | (51.16M) | — |
Net Income vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's LTM Mar 2026 net income of -$166.12M is the 8th highest of the 11 companies compared; the peer median is -$106.09M.
- Its year-over-year change of -770.3% is the lowest of 11, against a peer median of -18.4%.
- Net income amounts to 2895.1% of revenue for TRDA, versus a peer median of 246.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$43.51M | +23.8% | — | — |
| LTM Mar 2026 | -$51.99M | -12.6% | — | — | |
| LTM Mar 2026 | -$54.44M | +11.9% | — | — | |
| LTM Mar 2026 | -$78.67M | -15.4% | — | 173.5% | |
| LTM Mar 2026 | -$97.59M | -25.7% | — | 4840.8% | |
| LTM Mar 2026 | -$114.59M | -108.1% | — | — | |
| LTM Mar 2026 | -$116.64M | -37.7% | — | 319.6% | |
| LTM Mar 2026 | -$166.12M | -770.3% | — | 2895.1% | |
| LTM Mar 2026 | -$169.52M | -21.5% | — | — | |
| LTM Mar 2026 | -$173.76M | +31.1% | — | — | |
| LTM Mar 2026 | -$239.55M | -441.4% | — | 110.0% | |
| Peer median (excluding TRDA) | -$106.09M | -18.4% | — | 246.5% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 129.01M | 210.78M | 25.42M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.1M |
| Gross Profit | 0 | 0 | 129.01M | 210.78M | 21.33M |
| Gross Margin | — | — | 100.0% | 100.0% | 83.9% |
| Research & Development | 35.93M | 66.61M | 99.88M | 125.31M | 142.27M |
| Selling, General & Admin | 15.2M | 30.64M | 32.29M | 38.47M | 41.05M |
| Operating Expenses | 51.13M | 97.25M | 132.18M | 163.77M | 177.32M |
| Depreciation & Amortization | 1.12M | 1.9M | 2.84M | 3.77M | 425K |
| EBITDA | (50.04M) | (90.09M) | 14.9M | 70.26M | (142.4M) |
| EBITDA Margin | — | — | 11.5% | 33.3% | -560.2% |
| Operating Income | (51.13M) | (97.25M) | (3.16M) | 47.01M | (156M) |
| Operating Margin | — | — | -2.5% | 22.3% | -613.7% |
| Interest Income | 0 | 2.63M | 15.22M | 19.47M | 0 |
| Interest Expense | 0 | 2.63M | 0 | 0 | 0 |
| Other Income / Expenses | (31K) | 2.63M | 15.22M | 19.47M | 13.17M |
| Income Before Tax | (51.16M) | (94.62M) | 12.06M | 66.49M | (142.83M) |
| Pre-Tax Margin | — | — | 9.3% | 31.5% | -561.8% |
| Income Tax Expense | 0 | 0 | 18.74M | 859K | 924K |
| Net Income | (51.16M) | (94.62M) | (6.69M) | 65.63M | (143.75M) |
| Net Margin | — | — | -5.2% | 31.1% | -565.5% |
| EPS (Basic) | (1.60) | (2.79) | (0.20) | 1.76 | (3.47) |
| EPS (Diluted) | (1.60) | (2.79) | (0.20) | 1.68 | (3.47) |
| Weighted Avg Shares | 31.22M | 31.29M | 33.05M | 37.31M | 41.37M |
| Weighted Avg Shares (Diluted) | 31.22M | 31.29M | 33.05M | 39M | 41.37M |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.